Damora Therapeutics, Inc. short interest in 2023
In 2023, Damora Therapeutics, Inc.'s disclosed short interest ran from 0.33% of shares outstanding on 13 Jan 2023 to 1.13% on 29 Dec 2023, a change of +0.80 percentage points. The year's high was 2.54% on 13 Oct 2023 and its low 0.05% on 31 Mar 2023, averaging 0.65% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 2.10 days on 13 Oct 2023. Full history: Damora Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 0.33% (13 Jan 2023)
- End of year
- 1.13% (29 Dec 2023)
- Change
- +0.80 pp
- High
- 2.54% (13 Oct 2023)
- Low
- 0.05% (31 Mar 2023)
- Average
- 0.65%
- Highest days to cover
- 2.10 (13 Oct 2023)
- SEC filings marked
- 5
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 0.33% | 1.11 | results (8-K) |
| 31 Jan 2023 | 0.20% | 1.00 | |
| 15 Feb 2023 | 0.26% | 1.15 | |
| 28 Feb 2023 | 0.14% | 1.32 | |
| 15 Mar 2023 | 0.07% | 1.00 | 10-K filed |
| 31 Mar 2023 | 0.05% | 1.00 | |
| 28 Apr 2023 | 0.05% | 1.00 | 10-Q filed |
| 15 May 2023 | 0.05% | 1.00 | |
| 31 May 2023 | 0.05% | 1.00 | |
| 15 Jun 2023 | 0.05% | 1.00 | |
| 31 Jul 2023 | 0.84% | 1.00 | 10-Q filed |
| 15 Aug 2023 | 1.46% | 1.00 | |
| 31 Aug 2023 | 0.64% | 1.00 | |
| 15 Sep 2023 | 1.26% | 1.00 | |
| 13 Oct 2023 | 2.54% | 2.10 | |
| 31 Oct 2023 | 1.71% | 1.23 | |
| 15 Nov 2023 | 0.91% | 1.04 | 10-Q filed |
| 30 Nov 2023 | 0.68% | 1.73 | |
| 29 Dec 2023 | 1.13% | 1.00 |
See also: Damora Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.